Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer

Prostate Cancer

(2017) James Mohler et al.   Journal of the National Comprehensive Cancer Network

Her Wedding

(2012) Chadi Nabhan   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib and Sunitinib, Two Anticancer Drugs, Inhibit CYP3A4-Mediated and Activate CY3A5-Mediated Midazolam 1'-Hydroxylation

(2011) M. Sugiyama et al.   DRUG METABOLISM AND DISPOSITION

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer

(2008) W. L. Dahut et al.   CLINICAL CANCER RESEARCH

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

(2008) Dominik R. Berthold et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: A Phase II study

(2008) Mohammad Reza Safarinejad   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS